Thrombolysis for Acute Ischemic Stroke - Our Experiences as Part of SITS-MOST

Autor: Marina Roje-Bedeković, Vesna Vargek-Solter, Lejla Čorić, Karla Sabolek, Tomislav Breitenfeld, Višnja Supanc, Vida Demarin
Jazyk: angličtina
Rok vydání: 2009
Předmět:
Zdroj: Acta clinica Croatica
Volume 48
Issue 3
ISSN: 1333-9451
0353-9466
Popis: Thrombolysis with intravenous recombinant tissue plasminogen activator (rt-PA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cerebrovascular lesion. At University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, thrombolytic therapy with intravenous rt-PA (alteplase) (Actrlyse®) for acute ischemic stroke was introduced in 2004. We present our results referring to demographic, time logistics and clinical outcome data as part of SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) and compare them with the results from other centers in Croatia and all other participating centers. Up to now, 56patients (61% of male and 39% of female, average age 67 years) have been treated at our department with intravenous rt-PA (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given asabolus followed by 60-minute infusion. Our experiences with thrombolytic therapy with intravenous rt-PA (alteplase) (Aculyse®) for acute ischemic stroke confirm the safety and the efficacy of this therapy.
Tromboliza intravenskim rekombiniranim aktivatorom tkivnog plazminogena (rt-PA) je prvi dokazani učinkoviti način liječenja akutnog ishemijskog moždanog udara u svrhu smanjenja cerebrovaskularnog oštećenja. U Klinici za neurologiju Kliničke bolnice "Sestre milosrdnice", Zagreb, trombolitička terapija intravenskim rt-PA-om (alteplase) (Actilyse®) u bolesnika s akutnim ishemijskim moždanim udarom započela je 2004. godine. Predstavljamo naše dosadašnje rezultate, koji se odnose na demografske, vremenske i podatke o kliničkom ishodu bolesnika, prikupljene u sklopu SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) istraživanja. u svrhu usporedbe rezultata dobivenih u našem centru s rezultatima iz drugih centara Hrvatske i svijeta. Do sada je u našem centru trombolizom intravenskim rt-PA-om (0,9 mg/kg tjelesne težine, do maksimalno 90 mg). 10% doze primijenjene u bolusu, 90% doze u infuziju u trajanju od 60 minuta, liječeno 56 bolesnika (61% muškarci, 39% žene, prosječne životne dobi 67 godina). Naša iskustva u trombolitičkoj terapiji (alteplase) (Acrdyse®) u bolesnika sa akutnim ishemijskim moždanim udarom potvrđuju učinkovitost i sigurnost takvog načina liječenja.
Databáze: OpenAIRE
Externí odkaz: